Distribution agreements for Matritech's cancer test:
This article was originally published in Clinica
Executive Summary
Matritech has formed two marketing agreements for NMP22, its bladder cancer test, with Finnish company Wallac's German subsidiary and an unnamed Italian company. Matritech expects to release details concerning the Italian distributor by the end of the month. A distribution agreement with Boehringer Ingelheim, which was struck in 1994 (see Clinica No 617, p13), has been terminated by mutual consent, Matritech says. The test kit is an EIA to measure the amount of NMP in stabilised urine (see Clinica No 704, p 17).
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.